Related Experiment Video
Updated: Apr 30, 2026
An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
Using galectin-3 to reduce heart failure rehospitalization
Yang Xue1, Alan Maisel, W Frank Peacock
1Division of Cardiology, University of California San Diego, La Jolla, CA, USA.
Insights
Galectin-3, a biomarker for inflammation and fibrosis, is linked to heart failure readmissions and mortality. Measuring galectin-3 may help personalize heart failure management and improve patient outcomes.
Area of Science:
- Cardiology
- Biomarker Research
- Heart Failure Management
Background:
- Reducing short-term heart failure readmissions is a growing clinical concern.
- Galectin-3 is a biomarker associated with myocardial inflammation, fibrosis, and adverse cardiac remodeling.
- Elevated galectin-3 levels correlate with increased mortality and heart failure readmission risk.
Purpose of the Study:
- To explore the role of galectin-3 as a biomarker in heart failure management.
- To assess the predictive value of galectin-3 for adverse cardiovascular events.
- To evaluate the potential of galectin-3 in developing individualized risk profiles for heart failure patients.
Main Methods:
- Analysis of galectin-3 levels in heart failure patients.
- Correlation of galectin-3 levels with clinical outcomes, including mortality and readmissions.
- Comparison of galectin-3's predictive value against established biomarkers like natriuretic peptides.
Main Results:
- Galectin-3 is a biomarker of inflammation and fibrosis in heart failure.
- Higher galectin-3 levels are associated with increased risk of mortality and heart failure readmission.
- Galectin-3 provides incremental predictive value beyond natriuretic peptides for adverse events.
Conclusions:
- Galectin-3 shows potential as a key biomarker in future heart failure management strategies.
- Individualized risk assessment using galectin-3 can optimize resource allocation and treatment.
- Further research is needed to fully define galectin-3's role in clinical algorithms.
Abstract:
Increasing attention is being paid towards reducing short-term heart failure readmissions in recent years. Biomarkers such as galectin-3 are likely to play pivotal roles in future heart failure management strategies as they can provide objective information on various pathophysiologic processes involved in heart failure. Galectin-3 is a biomarker of inflammation and fibrosis, which is strongly associated with adverse remodeling of the myocardium and subsequent left ventricular dysfunction. Clinically, elevated galectin-3 levels are associated with increased risk for short- and long-term risk for mortality and heart failure readmission. Galectin-3 can provide incremental predictive value for adverse events over natriuretic peptides. Although significant work is still required to further define the role of galectin-3, it has the potential to become an important part of future heart failure management algorithms by helping to provide an individualized risk profile, which can be used to optimize resource allocation and improve treatment outcomes.
More Related Videos
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Related Concept Videos
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies
01:26Heart Failure Drugs: Inotropic Agents
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Cardiomyopathy V: Interprofessional Care
01:28Mitral Regurgitation IV: Nursing Management